Remove Drug Pricing Remove Packaging Remove Pharmaceutical Manufacturing
article thumbnail

Would the Industry Survive 200% Pharma Tariffs?

Pharma Marketing Network

Or would it unravel under the weight of economic retaliation, manufacturing disruptions, and rising drug prices? Table of Contents The Ripple Effects of Tariffs on Drug Pricing Manufacturing Dependencies and Global Disruption Impact on Pharma Marketing and Innovation Budgets Can the Industry Adapt or Will It Fracture?

article thumbnail

TekniPlex Healthcare Unveils New Barrier Protection Systems Plant

Pharmaceutical Commerce

Supporting sterile barrier packaging and supply chain resilience The Madison plant reinforces the TekniPlex Healthcare’s goal of assisting pharma and medical companies, which indirectly includes its downstream partners as well. How the Rise in Self-Injectables Is Impacting Pharmaceutical Manufacturing. Pharmaceutical Commerce.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

US trade tariffs and the potential impact on pharma supply chains

Pharmaceutical Technology

Miranda McLaren June 30, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook When Donald Trump was elected the 47 th president of the United States of America, the outlook for pharmaceuticals was unclear, with 55% of North American industry professionals expecting negative repercussions when surveyed by GlobalData later that month.

article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR). The MHLW is currently proposing discussions on the FY2023 drug price revision.

article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR). The MHLW is currently proposing discussions on the FY2023 drug price revision.

article thumbnail

Specialized Software Can Only Do So Much For 340B Programs

Proxsys Rx

That’s why helping health systems minimize data mismatches at the source is so critical to maximizing 340B savings 340B drug pricing program savings for a covered entity — and why meeting that challenge is a core component of our 340B software and service package.